Biochemical assay systems enable screening of large numbers of chemical substances in a large variety of high throughput screening (HTS) formats. These biochemical assays typically measure binding of the compound to the targeted molecule or the modulation of target activity.
Robust Assay Development
Robust assay development for biochemical screens is an important step to ensure the assay is optimised for accuracy, sensitivity, specificity, reproducibility and low interference. This reduces the risk of false positives and negatives and ensures the assay produces robust data.
Detection Methods
Detection methods for biochemical assays vary depending on the target but typically include:
- Fluorescence polarization (catalytic activity and binding)
- Fluorescence intensity (catalytic activity and binding)
- TR-FRET (catalytic activity and binding)
- AlphaScreen® (catalytic activity and binding)
- Luminescence (enzymatic and binding assays)
- Mass spectrometry (catalytic activity)
- Mass spectrometry (binding)
- Mass spectrometry intact mass (covalent binding)
- Absorbance based read-outs
- Radiometric assays
Advanced Technology Platforms
Evotec has developed one of the most advanced technology platforms in the world with over 12 million euros invested in its HTS facilities in the last 5 years alone. With extensive knowledge of all aspects of drug discovery and development, the company offers a comprehensive range of biochemical, cell-based or biophysical screening approaches for hit discovery, supporting either standalone or integrated projects. Furthermore, thanks to Evotec’s flexibility to screen either clients’ compound collections or its own high-quality library of >850,000 compounds, your HTS and hit identification project will have the highest chance of success.
